Eli Lilly and Company (NYSE: LLY) announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.
The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of four different doses of LY2951742 given in a once-monthly, subcutaneous injection in more than 400 patients with episodic migraine (people who experience between four and 14 migraine headache days per month).
The primary objective was to assess whether at least one dose of LY2951742 was superior to placebo in the prevention of migraine headache. LY2951742 demonstrated a statistically significant reduction in migraine headache days and a safety and tolerability profile confirming the previous results seen in a Phase 2a study.
Lilly will present data from this trial in a late-breaking session at the 57th Annual American Headache Society meeting on June 20 in Washington D.C., and will submit data from the study for additional disclosure at scientific meetings and in peer-reviewed journals.
"We're encouraged by the results from this positive Phase 2b study that confirms the safety and efficacy profile of LY2951742," said David Ricks, Lilly senior vice president, and president of Lilly Bio-Medicines. "These results reinforce our confidence in the potential of this medicine to be a significant option for the preventive treatment of debilitating headache disorders like migraine and cluster headache."
In addition to the migraine program, Lilly has initiated two Phase 3 trials with LY2951742 in patients suffering from cluster headache. Based on the unmet medical need and significance of this disorder for patients, Lilly has been granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for cluster headache.
High diastolic blood pressure linked to increased migraine risk in women